ICICI Securities has maintained a Buy rating on Mahindra & Mahindra, raising its target price to Rs 4,100 from Rs 4,000, implying 25% upside from the current market price of Rs 3,284.
News in Focus


IDBI Capital has reiterated a Buy rating on Home First Finance Company, setting a target price of Rs 1,400, implying 19% upside from the current market price of Rs 1,181.

ICICI Securities has maintained a Buy rating on Suzlon Energy, retaining an unchanged target price of Rs 65, implying 35% upside from the current market price of Rs 48.

ICICI Securities has reiterated a Buy rating on Tata Power Company, maintaining a target price of Rs 485, implying 31% upside from the current market price of Rs 371.

ICICI Securities has maintained a Buy rating on Coforge Limited, setting a target price of Rs 1,950, implying a 17% upside from the current market price of Rs 1,669.

ICICI Securities has maintained a Buy rating on Bharat Electronics, setting a target price of Rs 530, implying a 35% upside from the current market price of Rs 394.
Main Regional Stories

Axis Securities has maintained a Buy rating on NTPC, though it has trimmed the target price slightly to Rs 420 from Rs 430, implying a 20% upside from the current market price of Rs 350.

ICICI Securities has maintained a Buy rating on Steel Authority of India, setting a target price of Rs 225, implying a 36% upside from the current market price of Rs 165.

Axis Securities has maintained its Buy rating on Bank of Baroda, though it has trimmed the target price to Rs 290 from Rs 315, implying an 18% upside from the current market price of Rs 246.6.

Axis Securities has reiterated a Buy rating on Greenply Industries Limited, raising its target price to Rs 355 from Rs 340, implying a 19% upside from the current market price of Rs 298.
After touching an intraday high of 15,683.03 and low of 15,524.68, the BSE Sensex finally settled at 15,565.55 after making a gain of 15.42 points, whereas the broad-based NSE Nifty ended at 4,566.05, up 3.95 points.
Today, fertiliser scrips commanded the gainer
or the first quarter ended June 2007, Pune-based Tech Mahindra’s conso
New Delhi: Actuated by maturation in key emerging markets, India’s leading pharmaceutical company Ranbaxy Laboratories’ net profit for the quarter ended June 30 climbed up 118 percent to Rs 266.2 crore from Rs 122.11 crore in the corresponding period of the last year. 








